Tisagenlecleucel is a chimeric antigen receptor (CAR) T-cell therapy for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma and children and young adults with relapsed or refractory acute lymphoblastic leukemia.
CADTH undertook a review of manufacturer-submitted materials and published literature to assess the clinical impact, cost-effectiveness, and implementation considerations, including patient and caregiver perspectives and experiences, ethical considerations, and other considerations, such as facilities for the administration of CAR T-cell therapy, therapy eligibility, travel requirements, and resource costs associated with the provision of tisagenlecleucel therapy in Canada.
The project has following key components:
- clinical systematic review
- economic review
- review of implementation considerations, ethics, and patient and caregiver perspectives and experiences
- recommendations report.
Read more about CAR T-cell therapy reviews at CADTH.
antigen, antigens, cancer, genetics, leukemia, lymphoma, pediatrics, precursor b-cell lymphoblastic leukemia-lymphoma, Acute lymphoblastic leukemia, CAR-T, CAR-T cells, CD19, CTL 019, CTL019, DLBCL, Diffuse, Kymriah, Large B-Cell, Receptors, T-Cell, all, chimeric antigen receptor